This segment focuses on the research, development, and production of protein-based drugs, including therapeutic monoclonal antibodies. Staidson leverages advanced protein engineering and cell line development technologies to create targeted therapies for various diseases. R&D efforts are directed towards improving antibody specificity, affinity, and stability. The therapeutic areas covered include infectious diseases, autoimmune disorders, and oncology. Clinical trials are conducted to evaluate the safety and efficacy of these protein therapeutics, with the goal of improving patient outcomes and quality of life. Staidson's market positioning in this segment is strengthened by its innovative antibody engineering platform and strategic collaborations with global partners.

Staidson is actively involved in the research and development of gene and cell therapy products. This segment utilizes cutting-edge technologies such as viral vectors and CRISPR-based gene editing to develop targeted therapies for genetic disorders and acquired diseases. R&D activities include optimizing gene delivery methods, enhancing gene expression, and minimizing off-target effects. The therapeutic areas of focus include oncology, rare diseases, and inherited metabolic disorders. Clinical trials are designed to assess the safety and efficacy of these gene and cell therapies, with the aim of providing long-term disease modification and improved patient outcomes. Staidson's competitive advantage in this segment lies in its expertise in gene editing technologies and its commitment to developing innovative therapies for unmet medical needs.

This segment encompasses the discovery, development, and commercialization of small molecule drugs targeting a wide range of therapeutic areas. Staidson employs advanced medicinal chemistry and high-throughput screening techniques to identify and optimize novel drug candidates. R&D efforts are focused on developing orally bioavailable and potent small molecules with improved pharmacokinetic properties. The therapeutic areas covered include nervous system disorders, gastrointestinal diseases, and urinary system conditions. Clinical trials are conducted to evaluate the safety and efficacy of these small molecule drugs, with the goal of providing effective and convenient treatment options for patients. Staidson's market positioning in this segment is supported by its strong R&D capabilities and its ability to identify and develop innovative small molecule drugs.